Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Assets (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Return on Assets for 15 consecutive years, with 1.95% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 245.0% to 1.95% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.95%, a 245.0% increase, with the full-year FY2024 number at 0.02%, up 29.0% from a year prior.
  • Return on Assets was 1.95% for Q3 2025 at NovaBay Pharmaceuticals, up from 1.27% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 1.95% in Q3 2025 to a low of 0.75% in Q1 2021.
  • A 5-year average of 0.02% and a median of 0.19% in 2022 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: tumbled -73bps in 2024, then surged 245bps in 2025.
  • NovaBay Pharmaceuticals' Return on Assets stood at 0.32% in 2021, then soared by 64bps to 0.12% in 2022, then plummeted by -206bps to 0.36% in 2023, then surged by 90bps to 0.03% in 2024, then surged by 5828bps to 1.95% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Return on Assets are 1.95% (Q3 2025), 1.27% (Q2 2025), and 1.68% (Q1 2025).